Gong Y, Liu KD, Zhou G, Xue Q, Chen SL, Tang ZY. Tumor radioimmunoimaging of chimeric antibody in nude mice with hepatoma xenograft. World J Gastroenterol 1998; 4(1): 7-9 [PMID: 11819217 DOI: 10.3748/wjg.v4.i1.7]
Corresponding Author of This Article
Prof. Kang-Da Liu, Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University, Shanghai 200032, China
Article-Type of This Article
Original Articles
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 15, 1998; 4(1): 7-9 Published online Feb 15, 1998. doi: 10.3748/wjg.v4.i1.7
Tumor radioimmunoimaging of chimeric antibody in nude mice with hepatoma xenograft
Yi Gong, Kang-Da Liu, Ge Zhou, Qiong Xue, Shao-Liang Chen, Zhao-You Tang
Yi Gong, Kang-Da Liu, Ge Zhou, Qiong Xue, Zhao-You Tang, Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University, Shanghai 200032, China
Shao-Liang Chen, Institute of Nuclear Medicine, Zhongshan Hospital, Shanghai Medical University, Shanghai 200032, China
Yi Gong, female, born in 1971 in Shanghai, graduated from Shanghai Medical University in 1994, Master degree of internal medicine.
Author contributions: All authors contributed equally to the work.
Correspondence to: Prof. Kang-Da Liu, Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University, Shanghai 200032, China
Telephone: +86-21-64041990 ext. 2295.
Received: September 20, 1997 Revised: November 22, 1997 Accepted: December 20, 1997 Published online: February 15, 1998
Abstract
AIM: To study the radioimmunoimaging (RAII) using the human/mouse chimeric Ab to evaluate its targeting activity in animal models.
METHODS: To chimeric Ab was labeled with 131I. RAII was performed at different intervals after injection of radio-labeled Abs in nude mice with human hepatoma xenograft, and tissue distribution of radioactivity was measured. Comparison was made in the chimeric Ab between the single segment Ab and previous murine mAb against HBxAg.
RESULTS: The experimental objects developed tumor-positive image after 2 days of radio-labeled Abs injection, and the peak accumulation of radioactivity fell on the 7th day. The tumor/liver ratioactivity of the chimeric Ab, single segment Ab, anti-HBx mAb, and the control group was 281 ± 0.21, 2.44 ± 0.16, 4.60 ± 0.19, and 0.96 ± 0.14, respectively.
CONCLUSION: The genetic engineering Abs have a considerable targeting activity which can be used as a novel humanized vector in the targeting treatment of liver cancer.
